Compare Bristol-Myers Squibb Co (BMY) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs United Microelectronics Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.86 (market cap $129.94B), while United Microelectronics Corp trades at $19.38 (market cap $47.81B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.7× United Microelectronics Corp's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | UMC | |
|---|---|---|
Market Cap | $129.94B | $47.81B |
Sector | Health | Technology |
52-Week High | $65.89 | $28.02 |
52-Week Low | $42.60 | $6.58 |
Enterprise Value | $163.92B | $44.93B |
Dividend Yield | 3.96% | 2.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
UMC trades at $18.79, up 0.37% today, with a bearish technical signal. Recent earnings beats and strong July 2026 sales growth of 18.98% year-over-year highlight operational momentum. The company is expanding capacity in Singapore and Taiwan to meet AI-driven demand, supported by a robust balance sheet with $115.24 billion in cash. However, net income margin has declined from 32.1% in 2022 to 16.99% in 2025, posing a concern.
The outlook is mixed; expansion initiatives and AI tailwinds offer growth potential, but margin compression and a bearish technical stance present risks. Analyst consensus is cautious with 53.33% hold ratings. Key catalysts include Q3 2026 earnings and fab expansion progress, while competitive pressures and macroeconomic volatility remain headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
